Strategic Global Advisors, LLC

Position in EXEL — Exelixis, Inc.

CIK 1580212 NEWPORT BEACH, CA

Position in EXEL

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$5,318,414

+$1,267,883 QoQ

Shares Held

97,747

+3.5% QoQ

Ownership

0.039%

of shares outstanding

% of Portfolio

0.76%

of 13F equity value

Holder Rank

#168

of 754 holders

Holding Since

Mar 2024

10 quarters on record

Voting authority Sole 44% Shared 0% None 56%

Healthcare · as of Jun 30, 2026

Strategic Global Advisors, LLC holds $8,606,227 across 4 Biotechnology names. EXEL ranks #1 (61.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	EXEL	Exelixis, Inc. This page	97,747	$5,318,414
2	ALNY	Alnylam Pharmaceuticals, Inc.	4,823	$1,451,867
3	ASND	Ascendis Pharma A/S	3,910	$1,042,875
4	ONC	BeOne Medicines Ltd.	2,783	$793,071

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$5,318,414	97,747	+3.5%	Shares	Sole	2026-08-14
2026-03-31	$4,050,531	94,440	-1.9%	Shares	Sole	2026-05-15
2025-12-31	$4,220,390	96,290	-2.2%	Shares	Sole	2026-02-13
2025-09-30	$4,065,572	98,440	-1.6%	Shares	Sole	2025-11-14
2025-06-30	$4,411,967	100,090	+6.5%	Shares	Sole	2025-08-14
2025-03-31	$3,470,886	94,011	-2.9%	Shares	Sole	2025-05-15
2024-12-31	$3,224,472	96,831	+4.1%	Shares	Sole	2025-02-14
2024-09-30	$2,414,284	93,036	-1.0%	Shares	Sole	2024-11-14
2024-06-30	$2,111,213	93,957	+1.9%	Shares	Sole	2024-08-14
2024-03-31	$2,187,170	92,169	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.